20 Jul Outpace Bio
Eric Soller, Ph.D., Chief Business Officer
Oct. 7 | 1:30pm | FLW Ballroom F
Seattle, WA
(Private)
Outpace Bio is a clinical-stage biotechnology company reprogramming cell therapies to overcome the challenges in solid tumors. By integrating unrivaled AI-powered protein design with advanced T cell engineering, Outpace creates programmable medicines designed to function more safely, effectively and at scale. The company’s modular platform—developed by scientific leaders in computational protein design and synthetic biology—builds on the breakthroughs recognized by the 2024 Nobel Prize in Chemistry. Outpace’s technologies are designed to improve function inside patients – enhancing trafficking, functional persistence, and tumor killing while minimizing toxicity. Backed by a world-class syndicate of investors, Outpace is advancing a pipeline of next-generation CAR and TCR T cell therapies with the potential to deliver curative outcomes for patients who have limited treatment options. The company is headquartered in Seattle, Washington.
